Hospital do Rim from Universidade Federal de São Paulo (dialysis center) where 208 patients make use of human recombinant erythropoietin (ESA) for anemia management. Structured interviews with personnel were arranged to identify workflow for anemia management. Time spent in each activity was registered using a stop watch by a trained professional. Time spent in less frequent activities or in activities were the direct relation with anemia management could not be done were not taken into consideration for this study. For valuing time and supplies the dialysis center's costs data was considered. RESULTS: Total time spent for ESA administration by the dialysis center for the treatment of 208 patients was 75 days or R$19,758. Assuming the usage of C.E.R.A. in 100% patients of the center, the time spent by the staff would be 10 days or R$2683, representing an 86% reduction versus current practice. Costs of supplies needed for the administration were R$28,863 for those patients receiving conventional ESA and R$774 if patients would have received C.E.R.A. As a result, potential total savings generated with the use of C.E.R.A. was R$ 45,165 per year in this dialysis center or R$ 217/patient/year. CONCLUSION: The study suggests that the adoption of once-monthly C.E.R.A. can bring substantial savings for the dialysis center: R$44,847 per year or R$216 per patient per year. Once-monthly C.E.R.A. could also improve resource utilization and enable health care staff to focus more time on other aspects of patient care. (HRQL). The positive effects of fesoterodine (FESO) and tolterodine extended release (TER) have been established in subjects with OAB using patientreported outcomes. This analysis assessed the effects of FESO and TER on individual items of the King's Health Questionnaire (KHQ). METHODS: This is a post hoc analysis of data from a multicenter, double-blind, placebo (PBO)-controlled trial. Eligible subjects with frequency and urgency or urgency urinary incontinence were randomized to PBO, FESO 4 mg, FESO 8 mg, or TER 4 mg for 12 weeks. Subjects completed the KHQ at baseline and end of treatment. The KHQ includes 9 domains with 21 items and a Symptom Severity scale; lower scores indicate better HRQL. Analysis of covariance was used to assess treatment-related effects on the 21 individual items of the 9 KHQ domains, with treatment and region as factors and baseline value as a covariate. RESULTS: By the end of the study, FESO 8 mg significantly improved responses to 13 items vs. PBO; in comparison, FESO 4 mg and TER improved responses to 9 and 8 items, respectively (all P < 0.01). There were no significant differences between treatment groups. Seven items did not improve with any treatment; most of these items were part of the Personal Relationships and General Health Perception domains. In general, items that improved the most with treatment had higher baseline values (ie, worse HRQL) compared with those that did not improve. CONCLUSION: Both doses of FESO (4 and 8 mg) significantly improved HRQL in subjects with OAB as evidenced by significantly better scores for 9 and 13 items of the KHQ vs PBO, respectively. The domains showing improvement were those for which improvement with OAB treatment would be expected.
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